Price
CHART BY
Historical dividends and forecast
The next dividend will be paid on 20.03.2026
CHART BY
Frequently asked questions
What is Regeneron Pharms's market capitalization?
What is Regeneron Pharms's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Regeneron Pharms?
What are the analyst ratings and target price for Regeneron Pharms's stock?
What is Regeneron Pharms's revenue over the trailing twelve months?
What is the free float of Regeneron Pharms's shares?
Financials
- Market Cap
- $77.93B
- EPS (TTM)
- $41.57
- Free Float
- 101.14M
- P/E ratio (TTM)
- 17.87
- Revenue (TTM)
- $14.34B
Pricing
- 1D span
- $731.54$740.36
- 52W span
- $477.00$820.45
Analyst Ratings
The price target is $863.42 and the stock is covered by 30 analysts.
Buy
21
Hold
9
Sell
0
Information
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- REGN